Vikas R. Dharnidharka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Vikas R. Dharnidharka has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Kevin C. Abbott
Nephrology, Walter Reed National Military Medical Center, Bethesda, MD
3 shared publications George A. Richard
The Division of Pediatric Nephrology, Shands Children's Hospital and University of Florida College of Medicine, Gainesville, Florida, USA
2 shared publicationsLawrence Y. Agodoa
2 shared publications- A. Chen
Department of Pediatrics, Stanford University, CA
1 shared publication - Anthony A. Portale
Division of Pediatric Nephrology, Department of Pediatrics, 533 Parnassus Ave, UC Hall Box 0748, San Francisco, CA 94143, USA
1 shared publication Arno Zaritsky
University of Florida College of Medicine
1 shared publication
Latest Publications
- Open Access
- 25 September 2012
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (10) , 2710-2718
A Peripheral Blood Diagnostic Test for Acute Rejection in Renal Transplantation
- 25 September 2012
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (10) , 2710-2718
Open AccessA Peripheral Blood Diagnostic Test for Acute Rejection in Renal Transplantation
- Open Access
- 6 January 2012
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (4) , 976-983
Associations Between EBV Serostatus and Organ Transplant Type in PTLD Risk: An Analysis of the SRTR National Registry Data in the United States
- 6 January 2012
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (4) , 976-983
Open AccessAssociations Between EBV Serostatus and Organ Transplant Type in PTLD Risk: An Analysis of the SRTR National Registry Data in the United States
- 1 January 2010
- Published by Springer Nature
- p. 183-185
Research Priorities and Future Directions
- Open Access
- 1 March 2007
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (3) , 662-666
Younger Age and Antibody Induction Increase the Risk for Infection in Pediatric Renal Transplantation: A NAPRTCS Report
- 1 March 2007
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (3) , 662-666
Open AccessYounger Age and Antibody Induction Increase the Risk for Infection in Pediatric Renal Transplantation: A NAPRTCS Report
- Open Access
- 1 March 2007
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (3) , 653-661
Risk Factors for Hospitalization for Bacterial or Viral Infection in Renal Transplant Recipients-An Analysis of USRDS Data
- 1 March 2007
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (3) , 653-661
Open AccessRisk Factors for Hospitalization for Bacterial or Viral Infection in Renal Transplant Recipients-An Analysis of USRDS Data
- Open Access
- 1 January 2007
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 2 (1) , 100-106
Effects of Urinary Tract Infection on Outcomes after Renal Transplantation in Children
Urinary tract infection (UTI) is the most common infection after kidney transplantation. A previous analysis showed that late (>6 mo after transplantation) UTI is associated with earlier graft loss in adults. It was hypothesized that children who are younger than 18 yr would be at higher risk to develop UTI and develop graft loss after both early and late UTI. The US Renal Data System database was analyzed from 1996 to 2000 for Medicare claims (composite of inpatient and outpatient) for UTI up to 36 mo after transplantation. SPSS software and Cox regression models were used to determine association of UTI and age after adjustment for covariates. Early UTI was defined as occurring P < 0.001) but not after late UTI (AHR 2.09; 95% CI 0.56 to 7.80; P = 0.27). Risk for posttransplantation death was not increased significantly after either early UTI (AHR 1.23; 95% CI 0.37 to 4.08) or late UTI (relative risk 2.22; 95% CI 0.90 to 5.44). Boys aged 2 to 5 (versus age 13 to <18 years) were at significantly higher risk for UTI. In girls, only those in the youngest age category (0 to 1) had higher risk for UTI. Children are at greater risk for graft loss after early but not necessarily late UTI. UTI was not an independent predictor of death in this population.
- 1 January 2007
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 2 (1) , 100-106
Open AccessEffects of Urinary Tract Infection on Outcomes after Renal Transplantation in Children
Urinary tract infection (UTI) is the most common infection after kidney transplantation. A previous analysis showed that late (>6 mo after transplantation) UTI is associated with earlier graft loss in adults. It was hypothesized that children who are younger than 18 yr would be at higher risk to develop UTI and develop graft loss after both early and late UTI. The US Renal Data System database was analyzed from 1996 to 2000 for Medicare claims (composite of inpatient and outpatient) for UTI up to 36 mo after transplantation. SPSS software and Cox regression models were used to determine association of UTI and age after adjustment for covariates. Early UTI was defined as occurring P < 0.001) but not after late UTI (AHR 2.09; 95% CI 0.56 to 7.80; P = 0.27). Risk for posttransplantation death was not increased significantly after either early UTI (AHR 1.23; 95% CI 0.37 to 4.08) or late UTI (relative risk 2.22; 95% CI 0.90 to 5.44). Boys aged 2 to 5 (versus age 13 to <18 years) were at significantly higher risk for UTI. In girls, only those in the youngest age category (0 to 1) had higher risk for UTI. Children are at greater risk for graft loss after early but not necessarily late UTI. UTI was not an independent predictor of death in this population.
- 27 June 2006
- Published by Wolters Kluwer Health in Transplantation
- Vol. 81 (12) , 1662-1667
Infection Frequency and Profile in Different Age Groups of Kidney Transplant Recipients
Older transplant recipients have been shown to be at greater risk for infectious death than younger adults, but no study to date has looked at relative risk of infection and infection profile differences for children versus adults, which may be very different from one another. Data from primary Medicare renal transplant recipients between 1991 and 1998 (n=64,751), as reported in the United States Renal Data System (USRDS), were analyzed for Medicare claims (both inpatient and outpatient) for infection and type of infection in the first year posttransplant. Cox regression was used to model adjusted hazard ratios (AHR) for infection. Total infections among renal transplant recipients increased significantly in more recent years. Patients transplanted in or after 1995 had a significantly higher adjusted risk for infection compared to those transplanted earlier (AHR 1.34, 95% CI=1.29-1.39). Older adults > or = 51 years of age had the highest percentage of experiencing infection, as compared to adults between 18-50 years and children < or = 17 years (P<0.001). Children were at highest risk of viral infection prior to 1995 but at lowest risk of viral infection after 1995, whereas elderly adults were at highest risk of bacterial infection throughout the study. Children experienced more claims for viral infections, whereas older transplant recipients experienced more claims for bacterial infections. The two extremes of transplant recipient age display very different risks for infection claim frequency and profile.
- 27 June 2006
- Published by Wolters Kluwer Health in Transplantation
- Vol. 81 (12) , 1662-1667
Infection Frequency and Profile in Different Age Groups of Kidney Transplant Recipients
Older transplant recipients have been shown to be at greater risk for infectious death than younger adults, but no study to date has looked at relative risk of infection and infection profile differences for children versus adults, which may be very different from one another. Data from primary Medicare renal transplant recipients between 1991 and 1998 (n=64,751), as reported in the United States Renal Data System (USRDS), were analyzed for Medicare claims (both inpatient and outpatient) for infection and type of infection in the first year posttransplant. Cox regression was used to model adjusted hazard ratios (AHR) for infection. Total infections among renal transplant recipients increased significantly in more recent years. Patients transplanted in or after 1995 had a significantly higher adjusted risk for infection compared to those transplanted earlier (AHR 1.34, 95% CI=1.29-1.39). Older adults > or = 51 years of age had the highest percentage of experiencing infection, as compared to adults between 18-50 years and children < or = 17 years (P<0.001). Children were at highest risk of viral infection prior to 1995 but at lowest risk of viral infection after 1995, whereas elderly adults were at highest risk of bacterial infection throughout the study. Children experienced more claims for viral infections, whereas older transplant recipients experienced more claims for bacterial infections. The two extremes of transplant recipient age display very different risks for infection claim frequency and profile.
- Open Access
- 10 November 2005
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (19) , 2085-2086
Costimulation Blockade with Belatacept in Renal Transplantation
The recent trial of belatacept in renal transplantation (Aug. 25 issue)1 reveals three cases of post-transplantation lymphoproliferative disorder. Two of the patients with the disorder had a primary Epstein–Barr virus (EBV) infection. The promise of belatacept is greater specificity in the suppression of the immune response.2 Theoretically, therefore, the use of belatacept should not prevent the development of primary immunity against EBV if the virus is introduced in patients with an allograft. It would be interesting to know from the authors whether the primary infection in these two patients was secondary to an EBV seromismatch at transplantation or was subsequently acquired in the community. The simultaneous use of basiliximab, mycophenolate mofetil, and glucocorticoids with belatacept may have been counterproductive, since these are nonselective immunosuppressive agents that could have hindered the development of primary immunity to EBV. Basiliximab, which was initially touted as being selective for activated T cells, may also increase the risk of post-transplantation lymphoproliferative disorder.3 The true value of belatacept in relation to this disorder may thus be evident only in trials that do not incorporate the use of nonselective immunosuppressive agents.
- 10 November 2005
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (19) , 2085-2086
Open AccessCostimulation Blockade with Belatacept in Renal Transplantation
The recent trial of belatacept in renal transplantation (Aug. 25 issue)1 reveals three cases of post-transplantation lymphoproliferative disorder. Two of the patients with the disorder had a primary Epstein–Barr virus (EBV) infection. The promise of belatacept is greater specificity in the suppression of the immune response.2 Theoretically, therefore, the use of belatacept should not prevent the development of primary immunity against EBV if the virus is introduced in patients with an allograft. It would be interesting to know from the authors whether the primary infection in these two patients was secondary to an EBV seromismatch at transplantation or was subsequently acquired in the community. The simultaneous use of basiliximab, mycophenolate mofetil, and glucocorticoids with belatacept may have been counterproductive, since these are nonselective immunosuppressive agents that could have hindered the development of primary immunity to EBV. Basiliximab, which was initially touted as being selective for activated T cells, may also increase the risk of post-transplantation lymphoproliferative disorder.3 The true value of belatacept in relation to this disorder may thus be evident only in trials that do not incorporate the use of nonselective immunosuppressive agents.
- Open Access
- 15 January 2004
- Published by Elsevier in American Journal of Transplantation
- Vol. 4 (3) , 384-389
Post-Transplant Infections Now Exceed Acute Rejection as Cause for Hospitalization: A Report of the NAPRTCS
- 15 January 2004
- Published by Elsevier in American Journal of Transplantation
- Vol. 4 (3) , 384-389
Open AccessPost-Transplant Infections Now Exceed Acute Rejection as Cause for Hospitalization: A Report of the NAPRTCS